Product Description
Mechanisms of Action: M2 Antagonist
Novel Mechanism: No
Modality: Large Molecule
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Avera
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Anesthesia Related
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2004-004728-11 |
2004-004728-11 | P2 |
Completed |
Anesthesia Related |
2005-12-13 |
2022-03-12 |
Treatments |
|
NCT00235976 |
MR/EUM202 | P2 |
Completed |
Anesthesia Related |
None |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|